Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Race Oncology Ltd. ( (AU:RAC) ) has shared an announcement.
Race Oncology Ltd. announced a change in the director’s interest, with Director Daniel Tillett acquiring an additional 22,000 fully paid ordinary shares through an on-market purchase. This transaction, valued at $58,744.03, increases his total holdings, reflecting a potential vote of confidence in the company’s future prospects and possibly impacting investor sentiment positively.
More about Race Oncology Ltd.
Race Oncology Ltd. operates in the biotechnology sector, focusing on the development of cancer therapies. The company is engaged in advancing its primary product, Bisantrene, which is aimed at treating various forms of cancer, thereby addressing significant unmet medical needs in the oncology market.
Average Trading Volume: 561,846
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$518.1M
For a thorough assessment of RAC stock, go to TipRanks’ Stock Analysis page.